BD

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Mittwoch, November 8, 2023
Cystoscopy, Standard of care, APM, Cevira, Stryker Corporation, BLC, Bladder cancer, FX, Cropping system, EBIT, Bank statement, BD, Growth, FDA citizen petition, CET, CFO, Patient, NOK, Tourism, Pharmaceutical industry, Renewable energy, EBITDA, Photocure

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Mittwoch, November 8, 2023
Cystoscopy, Standard of care, APM, Cevira, Stryker Corporation, BLC, Bladder cancer, FX, Cropping system, EBIT, Bank statement, BD, Growth, FDA citizen petition, CET, CFO, Patient, NOK, Tourism, Pharmaceutical industry, Renewable energy, EBITDA, Photocure

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

STERIS Announces Financial Results for Fiscal 2024 Second Quarter

Retrieved on: 
Dienstag, November 7, 2023
BD, Steris, Growth, Customer, NYSE, Health care, Dental, STE, AST, Video game

Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.

Key Points: 
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of fiscal 2023.
  • Adjusted net income (see Non-GAAP Financial Measures) for the second quarter of fiscal 2024 was $202.2 million or $2.03 per diluted share, compared with the previous year’s second quarter of $199.6 million or $1.99 per diluted share.
  • Dental second quarter revenue as reported declined 5% to $104.2 million compared with $109.6 million in the second quarter of fiscal 2023.
  • Reflecting lower volume, operating income was $24.5 million in the second quarter of fiscal 2024 compared with $28.1 million in the prior year’s second quarter.

Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland

Retrieved on: 
Dienstag, Oktober 31, 2023
Knowledge, Science, FDA, ZS Associates, Policy, Thought, MD, Strategic management, Conference, BD, Growth, Transport, Medicine, Partnership, Business, LSE, Investment, Patient, ZS, Longevity, Mental health, Pharmaceutical industry, Fine chemical

Miami, Florida--(Newsfile Corp. - October 31, 2023) - Microdose Psychedelic Insights announces details of a featured fireside chat titled "Pharma and Biotech Business Development: What Are Companies Exploring in Psychedelics?"

Key Points: 
  • Miami, Florida--(Newsfile Corp. - October 31, 2023) - Microdose Psychedelic Insights announces details of a featured fireside chat titled "Pharma and Biotech Business Development: What Are Companies Exploring in Psychedelics?"
  • The fireside chat will explore how major corporations are approaching business development and partnership opportunities in the emerging psychedelic medicine space.
  • As the pipeline of novel psychedelics has grown, so has pharma and biotech interest in partnering / investing with others who are developing new psychedelics.
  • In this fireside chat, Cody Powers and Steve Herbert will explore how pharma and biotech companies are assessing business development opportunities in psychedelics.

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

Retrieved on: 
Donnerstag, November 2, 2023
University of California, Davis, Regenerative medicine, California Institute for Regenerative Medicine, UC, Good manufacturing practice, Doctor of Philosophy, Health, BD, Medicine, CGT, Gene, Partnership, University, GMP, CIRM, Point, Patient, Fausto Pocar, POC, Pharmaceutical industry

“Our goal is to facilitate more accessible patient care production through collaboration with aligned expertise.

Key Points: 
  • “Our goal is to facilitate more accessible patient care production through collaboration with aligned expertise.
  • Both parties are interested in expanding on the point of care (POC) network model Orgenesis deploys by aligning the tools, experts, and resources needed to decentralize medical innovation.
  • “We are thrilled to see such a deserving team get support from their state to show the true value of decentralization in California,” Vered Caplan, CEO of Orgenesis commented.
  • To learn more about UC Davis and their pioneering work in the cell and gene therapy industry, please visit: https://health.ucdavis.edu/stemcellresearch/ .

Rising Digitalization to Revolutionize Healthcare Systems Boosting Pharmacy Automation Market Says Future Market Insights, Inc.

Retrieved on: 
Montag, November 6, 2023
Cloud, Omnicell, Automatic hyperlinking, Growth, Health information management, Pharmacy automation, Research, Artificial intelligence, Liss, FMI, BD, Research report, Prescription, Risk, Machine learning, Electronic health record, AI, Investment, Pharmacist, Automation, Robotics, Grocery store, Medical device, Pet industry, Generic drug, Pharmacy

NEWARK, Del., Nov. 6, 2023 /PRNewswire/ -- It is anticipated that the global pharmacy automation market would grow from US$ 6.1 billion in 2023 to US$ 13.3 billion by 2033. From 2023 to 2033, the market is anticipated to grow at a compound annual growth rate of 8.1%.

Key Points: 
  • Robotic systems automate several physical tasks involved in pharmacy operations, such as dispensing medications, packaging prescriptions, and transporting medications throughout the pharmacy.
  • "Interoperability allows pharmacy automation systems to communicate with other systems, such as electronic health records (EHRs) and laboratory information systems (LISs).
  • This can improve the efficiency of pharmacy operations and reduce the risk of errors, increasing focus on interoperability between pharmacy automation systems and other healthcare IT systems," opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
  • Recent Developments in the Pharmacy Automation Market:
    In 2023, Omnicell launched its new specialty pharmacy services offering to help health systems establish and optimize specialty pharmacy programs.

Rising Digitalization to Revolutionize Healthcare Systems Boosting Pharmacy Automation Market Says Future Market Insights, Inc.

Retrieved on: 
Montag, November 6, 2023
Cloud, Omnicell, Automatic hyperlinking, Growth, Health information management, Pharmacy automation, Research, Artificial intelligence, Liss, FMI, BD, Research report, Prescription, Risk, Machine learning, Electronic health record, AI, Investment, Pharmacist, Automation, Robotics, Grocery store, Medical device, Pet industry, Generic drug, Pharmacy

NEWARK, Del., Nov. 6, 2023 /PRNewswire/ -- It is anticipated that the global pharmacy automation market would grow from US$ 6.1 billion in 2023 to US$ 13.3 billion by 2033. From 2023 to 2033, the market is anticipated to grow at a compound annual growth rate of 8.1%.

Key Points: 
  • Robotic systems automate several physical tasks involved in pharmacy operations, such as dispensing medications, packaging prescriptions, and transporting medications throughout the pharmacy.
  • "Interoperability allows pharmacy automation systems to communicate with other systems, such as electronic health records (EHRs) and laboratory information systems (LISs).
  • This can improve the efficiency of pharmacy operations and reduce the risk of errors, increasing focus on interoperability between pharmacy automation systems and other healthcare IT systems," opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
  • Recent Developments in the Pharmacy Automation Market:
    In 2023, Omnicell launched its new specialty pharmacy services offering to help health systems establish and optimize specialty pharmacy programs.

BD Advances "One-Stick Hospital Stay" Vision with Launch of Next-Generation Needle-Free Blood Draw Technology

Retrieved on: 
Donnerstag, November 2, 2023
FDA, Becton, Standard of care, NYSE, Food, IV, Needlestick injury, Fear, Regulation of tobacco by the U.S. Food and Drug Administration, Health, Maintenance, BD, Clinical, BDX, Risk, Hospital, Workflow, Anxiety, Becton, Dickinson and Company headquarters, Patient, Medical imaging, Medical device

FRANKLIN LAKES, N.J., Nov. 2, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."  

Key Points: 
  • New Peripheral Line Draw Solution Delivers First and Only Compatibility with Integrated Catheters, Bringing Elevated Standard of Care to More U.S.
  • Hospitals
    FRANKLIN LAKES, N.J., Nov. 2, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company's vision of a "One-Stick Hospital Stay."
  • **Clinical studies were done on previous generations of the PIVO™ Blood Collection Device and Nexiva™ Catheter System.
  • PIVO™ Pro and Nexiva™ with NearPort IV Access are the next generations of their respective product families.

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Mittwoch, November 1, 2023
Female, Blood vessel, Maes, Kidney disease, Education, DCB, Freedom, MAE, TASC, Safety, Diabetes, Kaplan–Meier estimator, Research, Subgroup analysis, Meta-analysis, Pulmonary embolism, Death, BD, DVT, Detour, Clinical trial, Hypertension, Femoral vein, VIVA, TVR, Amputation, PTAB, Patient, Wynn Las Vegas, TLR, Medical imaging, Birth control, Pharmaceutical industry, Airline, SFA, Torus, EU

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • A total of 1,005 patients at 74 investigational sites were treated with the Lutonix 035 DCB and were followed to 36 months.
  • Freedom from TLR at 12 months was 88.6%, and freedom from primary safety events at 30 days was 98.2%.
  • DETOUR clinical data demonstrate the clinical utility of this novel therapy in long femoropopliteal lesions.

BioUtah Announces Headline Speakers for the 2023 Mayer Brown Utah Life Sciences Summit

Retrieved on: 
Mittwoch, Oktober 25, 2023
Summit, BD, Lake City, FDA, Myriad Genetics, Salt Palace, Telescopic sight

Salt Lake City, Utah--(Newsfile Corp. - October 25, 2023) - BioUtah, Utah's trade association serving the state's life sciences community, announced today an impressive line-up of speakers who will present at this year's 2023 Mayer Brown Utah Life Sciences Summit, November 9 at the Salt Palace Convention Center, in Salt Lake City.

Key Points: 
  • Salt Lake City, Utah--(Newsfile Corp. - October 25, 2023) - BioUtah, Utah's trade association serving the state's life sciences community, announced today an impressive line-up of speakers who will present at this year's 2023 Mayer Brown Utah Life Sciences Summit, November 9 at the Salt Palace Convention Center, in Salt Lake City.
  • BioUtah's Utah Life Sciences Summit presented by Mayer Brown is coming Nov. 9 to the Salt Palace Convention Center in Salt Lake City.
  • The Summit is Utah's premier life sciences event of the year, attracting record attendance.
  • Distinguished keynote speakers include: Joseph Smith, chief scientific officer, BD on medical device innovation.